Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전대원 | - |
dc.date.accessioned | 2019-04-18T02:20:13Z | - |
dc.date.available | 2019-04-18T02:20:13Z | - |
dc.date.issued | 2016-12 | - |
dc.identifier.citation | MEDICINE, v. 95, NO. 14, Page. 1-14 | en_US |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://oce.ovid.com/article/00005792-201604050-00004/HTML | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/102320 | - |
dc.description.abstract | Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN alpha-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n=349; HBeAg negative, n=90) with CHB who were treated with PEG-IFN alpha-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN alpha-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA<2000IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P=0.035; at PT6, 35.9% vs 13.3%, P=0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P<0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P<0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN alpha-2a. In naive Korean HBeAg-positive CHB patients treated with PEG-IFN alpha-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs. | en_US |
dc.description.sponsorship | This study was supported by partial research grants from F Hoff mann-La Roche (Korea). | en_US |
dc.language.iso | en | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.subject | CONTINUOUS ENTECAVIR THERAPY | en_US |
dc.subject | E-ANTIGEN SEROCONVERSION | en_US |
dc.subject | ON-TREATMENT PREDICTION | en_US |
dc.subject | PEGINTERFERON ALPHA-2A | en_US |
dc.subject | SUSTAINED RESPONSE | en_US |
dc.subject | STOPPING RULE | en_US |
dc.subject | HBV DNA | en_US |
dc.subject | HBEAG | en_US |
dc.subject | LAMIVUDINE | en_US |
dc.subject | COMBINATION | en_US |
dc.title | An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study | en_US |
dc.type | Article | en_US |
dc.relation.no | 14 | - |
dc.relation.volume | 95 | - |
dc.identifier.doi | 10.1097/MD.0000000000003026 | - |
dc.relation.page | 1-14 | - |
dc.relation.journal | MEDICINE | - |
dc.contributor.googleauthor | Chon, Young Eun | - |
dc.contributor.googleauthor | Kim, Dong Joon | - |
dc.contributor.googleauthor | Kim, Sang Gyune | - |
dc.contributor.googleauthor | Kim, In Hee | - |
dc.contributor.googleauthor | Bae, Si Hyun | - |
dc.contributor.googleauthor | Hwang, Seong Gyu | - |
dc.contributor.googleauthor | Heo, Jeong | - |
dc.contributor.googleauthor | Jang, Jeong Won | - |
dc.contributor.googleauthor | Lee, Byung Seok | - |
dc.contributor.googleauthor | Jun, Dae Won | - |
dc.relation.code | 2016002338 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | noshin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.